系统性硬化症中Th/To复合物抗体与癌症的关联分析
该病例对照研究纳入804例成人系统性硬化症(SSc)患者,比较403例有癌症史与401例无癌症史患者针对Th/To复合物组分(hPOP1、RPP25、RPP30、RPP40)的抗体。67例(8.3%)携带任一Th/To抗体,此类患者更常见局限皮肤型及肺间质病变或肺动脉高压,且在SSc起病2年内发生癌症的比例显著低于抗体阴性者(0% vs 11%,P=0.009)。
要点
- 8.3%的SSc患者携带抗Th/To复合物组分抗体,表型以局限皮肤型和肺部受累为主。
- 携带任一Th/To抗体者SSc起病2年内癌症发生率0%,显著低于抗体阴性者的11%(P=0.009)。
- Th/To抗体可能与同期癌症风险降低相关,但需进一步验证。
核心结论
- SSc患者若产生针对Th/To复合物组分的自身抗体,临床表型以局限皮肤型和肺部受累为特征。
- 携带任一Th/To自身抗体可能对同期癌症具有保护作用。
研究设计与样本
- 采用约翰霍普金斯硬皮病中心队列数据进行的病例对照研究,共纳入804例成人SSc患者。
- 比较401例至少病程5年无癌症史者与403例曾有癌症史者,采用免疫沉淀法检测抗hPOP1、RPP25、RPP30和RPP40抗体。
主要发现
- 804例中67例(8.3%)携带针对Th/To复合物任一组分的抗体。
- 携带任一组分抗体者更常见局限皮肤型疾病,较少出现肌腱摩擦音,更常见符合间质性肺病或肺动脉高压的表现。
- 携带抗hPOP1、RPP25、RPP30和/或RPP40抗体者在SSc起病2年内发生癌症的比例为0%,抗体阴性者为11%(P=0.009)。
关键数值与推荐
- Th/To复合物任一组分抗体阳性率为8.3%(67/804)。
- SSc起病2年内癌症发生率:Th/To抗体阳性者0%,抗体阴性者11%,P=0.009。
临床怎么用
- 对SSc患者检测Th/To复合物组分抗体有助于识别以局限皮肤型和肺部受累为特征的临床表型。
- Th/To抗体阳性提示SSc起病早期癌症风险可能较低,但不应据此替代常规癌症筛查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study is to describe 4 of the most common autoantibodies against components of the Th/To complex: human POP1 (hPOP1), RPP25, RPP30, and RPP40. We report their prevalence and clinical characteristics in a systemic sclerosis (SSc) population, and determine whether these specificities are associated with cancer. METHODS: A case-control study was performed using data from the Johns Hopkins Scleroderma Center Cohort. A total of 804 adult patients with SSc were included; 401 SSc patients with no history of cancer after at least 5 years of disease were compared to 403 SSc patients who ever had a history of cancer. Antibodies against hPOP1, RPP25, RPP30, and RPP40 were assayed by immunoprecipitation of 35 S-methionine-labeled proteins generated by in vitro transcription/translation. Demographic and clinical characteristics were compared between groups. RESULTS: Of 804 patients, 67 (8.3%) had antibodies against any component of the Th/To complex. Patients with antibodies to any component were significantly more likely to have limited cutaneous disease, less likely to have tendon friction rubs, and more likely to have findings consistent with interstitial lung disease or pulmonary hypertension. Patients with antibodies against hPOP1, RPP25, RPP30, and/or RPP40 were significantly less likely to develop cancer within 2 years of SSc onset (0% versus 11% of antibody-negative patients; P = 0.009). CONCLUSION: SSc patients who produce autoantibodies to components of the Th/To complex have a clinical phenotype characterized by limited cutaneous disease and pulmonary involvement. Our findings show that the presence of any Th/To autoantibody may have a protective effect against contemporaneous cancer.
引用
- Mecoli CA, Adler BL, Yang Q, et al. Cancer in Systemic Sclerosis: Analysis of Antibodies Against Components of the Th/To Complex. Arthritis Rheumatol. 2020. PMID: 33241644. doi:10.1002/art.41493
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。